PSMA-targeted PET in the Treatment of Prostate Cancer

This session focuses on techniques for markers placement and fiducials. Discussion includes how to incorporate PET imaging findings on radiation planning of prostate cancer. The speakers also discuss the integration of PSMA PET and practical tips. Review of new trial data and its application in the clinical setting is also presented. 

Target Audience

This activity is designed to meet the interests of radiation oncologists, physicists, radiation dosimetrists, radiation therapists and residents. 

Learning Objectives

Upon completion of this activity, participants should be able to do the following:

  • Work within multi-disciplinary teams to provide the highest level of care for patients. 
  • Understand the value of fiducial placement as it relates to the aggressive treatment of localized prostate cancer. 
  • Reduce toxicity during treatment for localized prostate cancer. 
  • Identify early stage disease with the use of PSMA PET. 
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.
Course opens: 
08/19/2024
Course expires: 
10/12/2026
Cost:
$0.00
Rating: 
0
  • Alexandra Diaz Pardo, MD, MS, is employed by The Ohio State University. Dr. Diaz receives honoraria as education/meeting faculty from ASTRO and ASCO. Dr. Diaz serves as Vice Chair of DEI with The Ohio State University.   
  • Chadwick L. Wright, MD, MS, PhD, is employed by the University of Cincinnati. Dr. Wright serves as a Member of the Board of Directors for the American Board of Science in Nuclear Medicine. 
  • Shauna McVorran, MD, MHSA, is employed by Geisel School of Medicine at Dartmouth and the Dartmouth Cancer Center.
  • Bhanu Prasad Venkatesulu, MD, MBBS, is employed by University of Pittsburgh Medical Center. Dr. Venkatesulu receives grant/research funding from Thomas Gore pancreatic cancer and Gateway to cancer research. Dr. Venkatesulu owns stock in ImmunityBio and Spectrum Pharmaceuticals. Dr. Venkatesulu serves as an Education committee member of ASTRO, a task force mentee with ICRP, an Adhoc member of RadOnc questions, and is a consultant on guidelines with the American Radium Society. 

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.

Price

Cost:
$0.00
Please login or register to take this course.